Ataciguat
As of the edition of 20 October 2026, Ataciguat is a small molecule: in active development; acts on GUCY1A1, GUCY1A2 and GUCY1B1 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 4, 0 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Nervous system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 4 |